CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Price & Overview
NASDAQ:CNTB • KYG235491019
Current stock price
The current stock price of CNTB is 2.99 USD. Today CNTB is up by 9.93%. In the past month the price increased by 21.54%. In the past year, price increased by 374.6%.
CNTB Key Statistics
- Market Cap
- 166.608M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.28
- Dividend Yield
- N/A
CNTB Stock Performance
CNTB Stock Chart
CNTB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CNTB. When comparing the yearly performance of all stocks, CNTB is one of the better performing stocks in the market, outperforming 98.47% of all stocks.
CNTB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTB. CNTB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CNTB Earnings
On November 12, 2025 CNTB reported an EPS of -0.31 and a revenue of 16.00K. The company beat EPS expectations (69.43% surprise).
CNTB Forecast & Estimates
11 analysts have analysed CNTB and the average price target is 8.06 USD. This implies a price increase of 169.5% is expected in the next year compared to the current price of 2.99.
For the next year, analysts expect an EPS growth of -212.62% and a revenue growth -99.83% for CNTB
CNTB Groups
Sector & Classification
CNTB Financial Highlights
Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 74.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.2% | ||
| ROE | -28.22% | ||
| Debt/Equity | 0 |
CNTB Ownership
CNTB Latest News, Press Relases and Analysis
CNTB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNTB
Company Profile
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Company Info
IPO: 2021-03-19
CONNECT BIOPHARMA HOLDINGS L
3580 Carmel Mountain Road, Suite 200
San Diego CALIFORNIA 215400 US
CEO: William Pan
Employees: 62
Phone: 18587271040
CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ
Can you describe the business of CONNECT BIOPHARMA HOLDINGS L?
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
What is the current price of CNTB stock?
The current stock price of CNTB is 2.99 USD. The price increased by 9.93% in the last trading session.
Does CONNECT BIOPHARMA HOLDINGS L pay dividends?
CNTB does not pay a dividend.
What is the ChartMill rating of CONNECT BIOPHARMA HOLDINGS L stock?
CNTB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB)?
CONNECT BIOPHARMA HOLDINGS L (CNTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).
What is the market capitalization of CNTB stock?
CONNECT BIOPHARMA HOLDINGS L (CNTB) has a market capitalization of 166.61M USD. This makes CNTB a Micro Cap stock.